FINWIRES · TerminalLIVE
FINWIRES

Biofuel's Weekly Value Changes Seen in Retail Prices for SAF, Renewable Diesel, The Digest Says

-- Weekly retail price for sustainable aviation fuel rose, renewable diesel dropped, and biodiesel remained unchanged, according to price assessments from The Digest.

For the week of Apr. 2-9, biodiesel's Renewable Fuel Standard value of $1.29 per gallon was unchanged from a week ago. Biodiesel's Low Carbon Fuel Standard value of $0.49/gal was unchanged from a week ago. Additionally, the biofuel's tax credit value at $1/gal and energy value of $3.27/gal were unchanged. Biodiesel's retail price of $6.05/gal on Thursday was unchanged from a week ago.

Renewable diesel's retail price of $6.71/gal this week is below $7/gal, down from last week. RD's energy value of $3.93/gal on Thursday was below $4.22/gal from a week ago. RD's RFS value is $1.29/gal, unchanged from a week ago. Its tax credit value at $1/gal was unchanged over the week. RD's LCFS value of $0.49/gal was also unchanged from a week ago.

Ethanol's weekly performance was mixed. Its LCFS value of $0.12/gal, energy value of $0.47/gal, and RFS value of $1.13/gal were unchanged from a week ago. The retail price of $1.72/gal was also unchanged from a week ago.

For sustainable aviation fuel, its energy value at $5.71/gal was above $5.33/gal a week ago. SAF's retail price of $9.03/gal was above $8.65 a week ago. SAF's RFS value was $1.29/gal, unchanged from a week ago. Its LCFS value was $0.49/gal, also unchanged from a week ago, and its tax credit value was unchanged at $1.54/gal.

Note: These values are for delivery into a US market with a clean-fuel standard. Conventional ethanol is modeled at a Carbon Intensity of 70, while RD, SAF, biodiesel, and cellulosic ethanol are modeled at a CI of 20, and green hydrogen at CI -5. Individual companies or processes may have CI scores that are higher or lower than those used to calculate LCFS credits.

相關文章

Asia

企業差旅管理公司預計將衝回至多1.18億英鎊的收入,與先前的業績相比將出現下滑。

根據週三提交給澳洲證券交易所的文件,Corporate Travel Management(ASX:CTD)預計將從2025財年及之前年度的業績中衝回至多1.18億英鎊的收入,高於此前預估的7760萬英鎊。 此前,該公司聘請畢馬威會計師事務所(KPMG)對部分年度的業績進行法務會計審查。畢馬威在審查中發現,該公司在英國已完成的客戶合約和其他收入的確認方面存在一些問題。 該公司表示,根據與部分客戶的商業談判結果,可能需要在上半年業績中衝回至多約1,000萬英鎊的收入。審查證實,部分客戶被收取了高於合約約定的費用。 Corporate Travel Management表示,已對其英國業務進行了“重大調整”,尤其是在財務控制和營運流程方面。該公司還補充說,審查並未在其他地區發現任何問題。 該公司計劃在今年第二季發布經審計的 2025 財年財務報表和經審核的 2026 財年上半年財務報表。

$ASX:CTD
Asia

北方星資源公司3月季度黃金銷售額下降

根據週三提交給澳洲證券交易所的文件,北方星資源公司(ASX:NST)表示,截至2025年3月季度,該公司黃金總銷量為380,807盎司,綜合維持成本(AISC)為每盎司2,709澳元。 先前提交的文件顯示,截至2025年3月季度,該公司黃金總銷量為385,441盎司,綜合維持成本為每盎司2,246澳元。 該公司預計2026財年黃金銷售量將超過150萬盎司,綜合維持成本預計在每盎司2,600澳元至2,800澳元之間。 該公司在支付3.47億澳元現金股利後,淨現金為3.2億澳元,截至3月31日,其現金及貴金屬總持有量為11.8億澳元。 北方之星資源公司(Northern Star Resources)的股價在最近的周三交易中下跌了約2%。

$ASX:NST
Asia

衛材與默克共同進行的腎癌藥物第三期臨床試驗未能達到存活終點

日本製藥公司衛材(Eisai,TYO:4523)和美國默克公司(Merck)的實驗性聯合療法在一項3期臨床試驗中未能達到無惡化存活期和總存活期這兩個主要終點。 根據週二發布的聯合聲明,該試驗旨在評估晚期透明細胞腎細胞癌(一種約佔所有腎癌病例80%的腎癌)的一線治療方案。 LITESPARK-012研究在1688名患者中測試了兩種方案:Keytruda合併Lenvima和Welireg,以及MK-1308A(Keytruda與一種在研抗體的複方製劑)合併Lenvima,並與已確立的Keytruda合併Lenvima方案進行比較。 中期分析顯示,與標準治療相比,兩種實驗性聯合方案均未能達到研究的兩個主要目標,即改善總存活期和無惡化存活期。

$TYO:4523